What Alcediag does

ALCEDIAG is a French precision diagnostics company headquartered in Montpellier and operating as a subsidiary of the diversified technology group ALCEN. Founded in 2013, the company develops blood-based molecular diagnostics for mental health, with its core focus on differentiating bipolar disorder from unipolar depression in adults presenting with moderate to severe depressive symptoms. Its lead product, EDIT-B, is a CE-marked in vitro diagnostic (IVDD 98/79/CE, Class 1) blood test that combines an 8-biomarker RNA editing panel with a machine learning algorithm incorporating patient clinical data (age, sex, treatments, addictions). Clinical validation across multiple European cohorts and 255+ patients has demonstrated sensitivity of 91%, specificity of 85%, and balanced accuracy of 0.901-0.904.

The company's technology backbone is the EDITECH platform, an integrated stack spanning DNA/RNA next-generation sequencing, epigenetic and RNA editing expertise, a bioinformatics pipeline, and AI/ML integration, with algorithms frozen during the operational phase to ensure safety, transparency, and reproducibility in a regulated medical context. ALCEDIAG's approach is protected by seven patent families and the company holds ISO 13485 certification. A second product, EDITOX, extends the platform into preclinical drug development via cell-based solutions that model drug impact on RNA editing.

Commercially, ALCEDIAG sells EDIT-B exclusively through medical biology laboratories on a per-test basis with results delivered to prescribing physicians within four weeks. The company launched in France in March 2024 via an exclusive partnership with Synlab (the test is branded myEDIT-B in Synlab markets), followed by Switzerland and Liechtenstein via Unilabs in late 2024/2025, and Italy in 2025 via Synlab. Reimbursement has not yet been secured; a 450-patient clinical utility study in France is underway to support payer decisions. The company's primary customer segments are psychiatrists and general practitioners prescribing the test, with clinical research partnerships (e.g., GHU Paris Psychiatrie & Neurosciences, Hospital Clinic Barcelona, Clariane) supporting evidence generation.

Name

Alcediag

Legal name

ALCEDIAG

Website

https://alcediag-alcen.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Alcediag is a French precision diagnostics subsidiary of ALCEN that develops CE-marked blood tests combining RNA editing biomarkers with machine learning to differentiate bipolar disorder from unipolar depression, serving psychiatrists and patients through exclusive European laboratory partners.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Precision diagnostics
• RNA editing biomarkers
• Molecular blood testing
• Psychiatric differential diagnosis
• In vitro diagnostics

Headquarters

HQ city

Montpellier

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. EDIT-B Diagnostic Test: Blood test for differentiating unipolar depression from bipolar disorder, prescribed by psychiatrists and general practitioners. Test performed exclusively in medical biology laboratories with results delivered within 4 weeks. Revenue generated per test performed.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Alcediag develops and commercializes RNA editing-based in vitro diagnostic blood tests, primarily EDIT-B®, which combines an 8-biomarker RNA editing panel with a machine-learning algorithm to differentiate bipolar disorder from unipolar depression in adult patients with moderate-to-severe depression. The company also offers EDITOX®, a cell-based preclinical tool for pharmaceutical drug development, all built on its integrated EDITECH® sequencing, bioinformatics, and AI platform.

Product overview

ALCEDIAG is an innovative diagnostic company specializing in precision psychiatry, offering a portfolio of blood tests, monitoring solutions, and companion diagnostics for mental health. The core product is EDIT-B®, a CE-marked blood test that differentiates unipolar depression from bipolar disorder using RNA editing-based biomarkers and AI. EDITOX® provides cell-based preclinical solutions for drug development applications. EDITECH® serves as the integrated technology platform, combining DNA/RNA sequencing, bioinformatics, and AI capabilities that underpin the diagnostic products. The company develops all solutions in-house, with seven patent families protecting its unique approach.

Differentiator

Problem solved

Functional benefit

Products and services

• EDIT-B® CE-marked in vitro diagnostic blood test that uses an 8-biomarker RNA editing panel combined with machine-learning algorithms to differentiate bipolar disorder from unipolar depression in adults presenting with moderate to severe depression. Prescribed by psychiatrists and general practitioners and performed in medical biology laboratories with results delivered within four weeks; demonstrated sensitivity above 80% and specificity of 85% in clinical validation cohorts.
• EDITOX® Cell-based solution designed to mimic the impact of drugs on RNA editing, used as a preclinical tool by pharmaceutical companies to advance new drug development and assess RNA editing responses to compounds.

Quantifiable outcome

• Sensitivity and specificity superior to 80% demonstrated in clinical trials
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

13 partnerships are on record, tiered minor and core.

• ClarianeminorStrategic or Co-development Partner · 15 October 2025Real-world clinical study collaboration presenting data on high acceptability of myEDIT-B test in routine care. Study involved 63 adult patients in France and Spain presented at ECNP congress.
• Synlab GroupcoreChannel Partner/ Reseller/ DistributorExclusive European partnership with Synlab group, Europe's market leader in medical laboratories, which has become myEDIT-B test's distributor. Test available in France and Italy under the myEDIT-B brand.
• EIT HealthcoreStrategic or Co-development PartnerEDIT-B Consortium co-funded by EIT Health and European Commission. Project aims to validate and commercialize a high-performance blood test to diagnose bipolar disorder using RNA editing biomarkers and AI.
• NeuroDeRiskminorStrategic or Co-development PartnerInnovative Medicines Initiative (IMI2) project providing tools for preclinical prediction of adverse effects of pharmaceuticals on the nervous system to de-risk drug candidates in R&D phases.
• Sys2Diag / CNRScoreTechnology or IntegrationRecurring partnership with Sys2Diag, a laboratory from CNRS (French National Center for Scientific Research), running cutting-edge research for innovation in medical diagnosis and next-generation medical interactives devices engineering.
• GHU Paris Psychiatrie & NeurosciencescoreStrategic or Co-development PartnerRecurring partnership with leading hospital player in mental illnesses and nervous system in France. GHU is a clinical trial site for EDIT-B studies.
• Hospital Clinic BarcelonacoreStrategic or Co-development PartnerRecurring partnership with leading healthcare, research and teaching center in Barcelona. Dr. Eduard Vieta serves as principal investigator and leads the bipolar disorder department.
• MIMSminorGTM or Marketing PartnerM accreditation from MIMS (House of Innovation in Personalized Medicine) for EDIT-B test. Recognition of innovation and trust granted by MIMS Scientific and Strategic Committee.
• Villa M / Groupe Pasteur MutualitéminorGTM or Marketing PartneriMpulsion-Villa M acceleration programme, an 8-month program bringing together innovative health and e-health startups to support deployment of innovative healthcare products.
• HopeStageminorGTM or Marketing PartnerCollaboration with combined company and association dedicated to supporting people with bipolar disorder. Founder Clément Baissat developed 4-step approach: AWARE – ACCEPT – GUIDE – SUPPORT. Mission to reduce stigma and help patients from first symptoms.
• France BiotechminorOthersMember of France Biotech, the French trade association of biotechnology companies.
• MedicenminorOthersMember of Medicen, the Île-de-France/Paris competitiveness cluster focusing on health, gathering more than 510 health innovators.
• EurobiomedminorOthersMember of Eurobiomed, the South of France competitiveness cluster dedicated to Healthtech, bringing together more than 400 industrial players, research laboratories, and universities.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Alto Neuroscience: Clinical-stage precision psychiatry company using biomarkers, EEG, and AI/ML to stratify patients with depression and other psychiatric conditions. Directly comparable to Alcediag in combining objective biological signals with machine learning to enable differential diagnosis and treatment selection in mental health.
• Veracyte: Commercial molecular diagnostics company that develops RNA-expression and genomic tests to resolve diagnostic ambiguity (e.g., in oncology). Highly comparable business model to Alcediag: laboratory-developed or IVD tests using RNA/genomic biomarkers, distributed via central labs, protected by IP and clinical validation.

Broad incumbents

• Myriad Genetics: Established molecular diagnostics company with a portfolio of germline and tumour genomic tests commercialised through specialty labs. Comparable to Alcediag in business model (proprietary biomarker tests, lab-based delivery, IP-protected menu) but operates at much greater scale and across oncology/women's health rather than psychiatry.
• Foundation Medicine (Roche): Roche-owned molecular diagnostics leader offering NGS-based profiling tests. Comparable to Alcediag in using NGS + AI/bioinformatics to convert complex molecular data into clinically actionable reports, but operating at vastly larger scale and focused on oncology rather than mental health.
• Exact Sciences: Diversified molecular diagnostics company (Cologuard, Oncotype DX, etc.) commercialising biomarker-based tests through clinical-lab channels. Similar diagnostic-platform commercial model to Alcediag, though at a much larger scale and across multiple non-psychiatric indications.
• QIAGEN: Global provider of molecular diagnostics assays, sample-prep technologies, and bioinformatics. Comparable to Alcediag in supplying RNA/DNA-based diagnostic workflows and bioinformatics pipelines to clinical labs, but as a tools-and-consumables provider rather than a test developer.

Emerging players

• Sage Therapeutics: Neuroscience company developing therapeutics for depression and other CNS indications with biomarker-driven patient selection. Adjacent to Alcediag's mental-health focus and shares the precision-psychiatry thesis, but operates on the therapeutic rather than diagnostic side.
• COMPASS Pathways: Mental-health company developing psilocybin therapy for treatment-resistant depression with biomarker-driven patient stratification. Comparable to Alcediag in targeting the depression-treatment paradigm with precision approaches, though focused on therapy delivery rather than diagnostic testing.
• P1vital: UK-based CNS research organisation developing experimental medicine tools and biomarkers for depression and other psychiatric conditions. Directly comparable to Alcediag in its focus on objective CNS biomarkers to support psychiatric drug development and differential diagnosis.

Others

• Genomics England: UK government-owned organisation sequencing patient genomes at population scale to enable rare-disease and cancer diagnostics. Comparable to Alcediag as an ecosystem enabler in genomic/RNA-based diagnostics, though operating as a public-sector platform rather than a commercial test developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@alcediagalcen3716
• LinkedInlinkedin.com/company/alcediag
• Xx.com/alcediag_alcen

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alcediag